FGFR3 Expression in Primary Invasive Bladder Cancers and Matched Lymph Node Metastases

Journal of Urology

Volumn 193, Issue 1, 2015, Pages 325-330

  Turo, Rafal ^a   Harnden, Patricia ^a   Thygesen, Helene ^a   Fleischmann, Achim ^b   Thalmann, George N ^b   Seiler, Roland ^b   Cross, William R ^a   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

carcinoma; fibroblast growth factor; neoplasm invasiveness; neoplasm metastasis; receptor; type 3; urinary bladder

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; CELL MEMBRANE; CYSTECTOMY; CYTOPLASM; FEMALE; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; UPREGULATION; BIOSYNTHESIS; BLADDER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSPECTIVE STUDIES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 84926133278     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.06.026     Document Type: Article

References (19)

1. 1 Cappellen, D., De Oliveira, C., Ricol, D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet, 23, 1999, 18.
2. 2 Tomlinson, D.C., Baldo, O., Harnden, P., et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol, 213, 2007, 91.
3. 3 Billerey, C., Chopin, D., Aubriot-Lorton, M.H., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol, 158, 2001, 1955.
4. 4 Bernard-Pierrot, I., Brams, A., Dunois-Lardé, C., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis, 27, 2006, 740.
5. 5 Tomlinson, D.C., Hurst, C.D., Knowles, M.A., Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene, 26, 2007, 5889.
6. 6 Miyake, M., Ishii, M., Koyama, N., et al. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther, 332, 2010, 795.
7. 7 Qing, J., Du, X., Chen, Y., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest, 119, 2009, 1216.
8. 8 Martinez-Torrecuadrada, J., Cifuentes, G., Lopez-Serra, P., et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res, 11, 2005, 6280.
9. 9 Gómez-Román, J.J., Saenz, P., Molina, M., et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res, 11, 2005, 459.
10. 10 Martinez-Torrecuadrada, J.L., Cheung, L.H., Lopez-Serra, P., et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther, 7, 2008, 862.
11. 11 Lamont, F.R., Tomlinson, D.C., Cooper, P.A., et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer, 104, 2011, 75.
12. 12 Zehnder, P., Studer, U.E., Skinner, E.C., et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int, 112, 2013, E51.
13. 13 Studer, U.E., Danuser, H., Merz, V.W., et al. Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol, 154, 1995, 49.
14. 14 Fleischmann, A., Thalmann, G.N., Markwalder, R., et al. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol, 23, 2005, 2358.
15. 15 Sobin, L., Gospodarowicz, M., Wittekind, C., TNM Classification of Malignant Tumours. 7th ed., 2009, Wiley and Sons, New York.
16. 16 Seiler, R., Thalmann, G.N., Rotzer, D., et al. CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod Pathol, 27, 2014, 87.
17. 17 Seiler, R., Thalmann, G.N., Fleischmann, A., MMP-2 and MMP-9 in lymph-node-positive bladder cancer. J Clin Pathol, 64, 2011, 1078.
18. 18 Fleischmann, A., Rotzer, D., Seiler, R., et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol, 60, 2011, 350.
19. 19 Sung, J.Y., Sun, J.M., Chang Jeong, B., et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol Oncol, 32, 2014, 49.e23.